Funding

Funding for the RareConnect project comes from several types of sources such as patient organisations (AFM), public funds (EAHC) and pharmaceutical companies. All funding supports the project as a whole and plays an essential part in launching and sustaining all participating rare disease communities.

Written by RareConnect team, published over 2 years ago.

AFM (French Association for Neuromuscular Disorders)

European Commission DG Health and Consumers
Alexion Pharmaceuticals
Celgene Corporation
Chiesi
DLA Piper

 

GSK

 

 

Novartis

 

 

Raptor Pharmaceuticals

The material only reflects the views of the author, and funders cannot be held responsible for any use which may be made of the information contained herein.

Written by RareConnect team, published over 2 years ago.

Comments are closed.